What is C4 Therapeutics Inc (CCCC) stock price today?

C4 Therapeutics Inc (CCCC) currently trades at $2.83 per share. The stock has a market capitalization of $281.02M and a P/E ratio of —x.

Is CCCC stock a buy, sell, or hold in 2026?

Based on WallStSmart's proprietary analysis, C4 Therapeutics Inc has a Smart Value Score of 37/100 (Grade D), resulting in a "Sell" investment rating. The Piotroski F-Score is —/9 and Altman Z-Score is —.

What is C4 Therapeutics Inc's revenue and earnings?

C4 Therapeutics Inc has trailing twelve-month (TTM) revenue of $35.95M with profit margins of -292.10%. Earnings per share (EPS) is $-1.27.

Is CCCC stock overvalued or undervalued?

Based on our DCF model, C4 Therapeutics Inc's intrinsic value is $6.64, representing a margin of safety of 72.44%. The stock currently trades at a P/E of —x.

CCCC

C4 Therapeutics Inc

NASDAQ: CCCC · HEALTHCARE · BIOTECHNOLOGY

$2.83

+10.55% today

Updated 2026-04-30

Market cap

$281.02M

P/E ratio

—

P/S ratio

7.82x

EPS (TTM)

$-1.27

Dividend yield

—

52W range

$1 – $4

Volume

3.0M

Market cap

$281.02M

P/E ratio

—

P/S ratio

7.82x

EPS (TTM)

$-1.27

Dividend yield

—

52W range

$1 – $4

Volume

3.0M

WallStSmart proprietary scores

out of 100

Grade: D

Sell

Investment rating

6.0

Growth

5.0

Quality

C+

2.0

Profitability

6.7

Valuation

—/9

Piotroski F-Score

—

Altman Z-Score

—

Industry rank

—

View all highly rated stocks (75+) →206 stocks currently score above 75

Price targets

Analyst target

$11.57

+308.83%

12-Month target

—

Intrinsic (DCF)

$6.64

Margin of safety

+72.44%

1 Strong Buy7 Buy0 Hold0 Sell0 Strong Sell

Price chart

X-Ray snapshot

Strengths

+ Revenue growth 112.80% QoQ

+ 72.44% below intrinsic value

Risks

- Thin margins at -292.10%

- Negative free cash flow $-22.16M

Key financials

Revenue Net Income Free Cash Flow

Metric	2022	2023	2024	2025	TTM
Revenue	$31.10M	$20.76M	$35.58M	$35.95M	$35.95M
Net income	$-128.18M	$-132.49M	$-105.32M	$-104.99M	$-20.49M
EPS	—	—	—	—	$-1.27
Free cash flow	$-111.44M	$-108.55M	$-65.34M	$-99.30M	$-22.16M
Profit margin	-412.19%	-638.34%	-295.96%	-292.08%	-292.10%

Recent insider activity

Date	Insider	Type	Shares	Price
2026-04-01	GROGAN, DONNA ROY	Buy	5,370	$2.70
2026-04-01	ANDERSON, KENNETH CARL	Buy	4,259	$2.70
2026-02-15	HIRSCH, ANDREW	Buy	20,400	—

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
CCCC	$281.02M	37	6.0	2.0	6.7	5.0	+72.44%	Hold
LLY	$760.43B	78	10.0	10.0	5.0	6.5	—	Strong Buy
JNJ	$547.28B	59	4.7	9.0	3.3	6.0	-43.54%	Buy
ABBV	$360.63B	63	4.0	8.0	4.7	5.0	-29.31%	Buy
UNH	$336.47B	54	5.3	5.5	7.3	4.8	+42.09%	Buy
AZN	$287.11B	64	6.7	8.0	5.3	5.0	+4.07%	Buy

Smart narrative

C4 Therapeutics Inc trades at $2.83. Our Smart Value Score of 37/100 indicates the stock is weak. TTM revenue stands at $35.95M. with profit margins at -292.10%. Our DCF model estimates intrinsic value at $6.64.

Frequently asked questions

What is C4 Therapeutics Inc's stock price?

C4 Therapeutics Inc (CCCC) trades at $2.83.

Is C4 Therapeutics Inc overvalued?

Smart Value Score 37/100 (Grade D, Sell). DCF value $6.64.

What is the price target of C4 Therapeutics Inc (CCCC)?

The analyst target price is $11.57, representing +308.8% upside from the current price of $2.83.

What is the intrinsic value of C4 Therapeutics Inc (CCCC)?

Based on our DCF model, intrinsic value is $6.64, a +72.4% margin of safety versus $2.83.

What is C4 Therapeutics Inc's revenue?

TTM revenue is $35.95M.

Company info

SectorHEALTHCARE

IndustryBIOTECHNOLOGY

CountryUSA

ExchangeNASDAQ

CurrencyUSD

Quick metrics

P/S ratio7.82x

ROE-44.40%

Beta2.86

50D MA$2.70

200D MA$2.44

Shares out0.10B

Float0.07B

Short ratio—

Avg volume3.0M

Performance

1 week—

1 month—

3 months—

YTD—

1 year—

3 years—

5 years—

Compare

CCCC vs LLY →CCCC vs JNJ →CCCC vs ABBV →Stock screener →